Abstract
It has been known for a relatively long time that progestogens, and especially medroxyprogesterone acetate (MPA), induce objective regression of the neoplasia in women with metastatic breast cancer. Some authors have recently reported [1, 7–9] that the response to MPA may be increased by employing high daily dosages. On this basis, we tested different dosages of MPA in patients who had become resistant to combined chemotherapy. Furthermore, we correlated the response of the patient with estrogen receptor status of the tumor.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Amadori D, Ravaioli A, Barbanti F (1977) The use of medroxyprogesterone acetate in high doses in palliative treatment of advanced mammary carcinoma (clinical experience with 44 cases). Minerva Med 68: 3967–3980
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–259
De Lena M, Brambilla C, Volagussa P, Bonadonna G (1979) High dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy. Cancer Chemother Pharmacol 2: 175–180
De Lena M, Brambilla C, Jirillo A (1980) Tamoxifen efficacy in advanced breast cancer previously treated with endocrine and cytotoxic therapy. Tumori 66: 339–348
Di Fronzo G, Bertuzzi A, Ronchi E (1968) An improved criterion for the evaluation of estrogen receptor binding data in human breast cancer. Tumori 64: 259–266
Ganzina F (1979) High dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review. Tumori 65: 563–585
Pannuti F, Martoni A, Lenaz CR, Piana E, Manni P (1978) A possible new approach to the treatment of metastatic breast cancer: Massive dose of medroxyprogesterone acetate. Cancer Treat Rep 62: 499–504
Pannuti F, Martoni A, Di Marco AR, Piana E, Saccani F, Becchi G, Mattioli G, Barbanti F, Marra GA, Persiani W, Cacciari L, Spagnuolo F, Polenzana D, Rocchetta G (1979) Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate ( MPA) in the treatment of metastatic breast cancer. J Cancer 15: 593–601
Robustelli Della Cuna G, Calciati A, Bernando Strada MR, Bumma C, Campio L (1978) High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a due response evolution. Tumori 64: 143–150
Scatchard G (1949) The attraction of protein for small molecules and ions. Ann NY Acad Sci 51: 660–672
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
De Lena, M., Villa, S., Di Fronzo, G. (1984). Therapeutic Activity of Medroxyprogesterone Acetate in Metastatic Breast Cancer: A Correlation Between Estrogen Receptors and Various Dosages. In: Leclercq, G., Toma, S., Paridaens, R., Heuson, J.C. (eds) Clinical Interest of Steroid Hormone Receptors in Breast Cancer. Recent Results in Cancer Research, vol 91. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82188-2_34
Download citation
DOI: https://doi.org/10.1007/978-3-642-82188-2_34
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82190-5
Online ISBN: 978-3-642-82188-2
eBook Packages: Springer Book Archive